202,900 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Purchased by Capricorn Fund Managers Ltd

Capricorn Fund Managers Ltd bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in the 1st quarter, according to its most recent disclosure with the SEC. The fund bought 202,900 shares of the biotechnology company’s stock, valued at approximately $1,932,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Phocas Financial Corp. acquired a new stake in BioCryst Pharmaceuticals during the fourth quarter worth approximately $1,956,000. Vanguard Group Inc. grew its position in shares of BioCryst Pharmaceuticals by 6.1% in the 3rd quarter. Vanguard Group Inc. now owns 21,790,881 shares of the biotechnology company’s stock valued at $165,393,000 after buying an additional 1,246,633 shares during the last quarter. Aberdeen Group plc acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter worth $7,126,000. BNP Paribas Financial Markets raised its stake in BioCryst Pharmaceuticals by 21.4% during the 4th quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock worth $19,833,000 after acquiring an additional 448,436 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al lifted its position in BioCryst Pharmaceuticals by 106.5% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock valued at $1,820,000 after acquiring an additional 120,350 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on BCRX shares. Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 9th. Cantor Fitzgerald boosted their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday. HC Wainwright reissued a “buy” rating and issued a $32.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Finally, Wedbush cut their target price on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $21.67.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX opened at $10.00 on Wednesday. The stock has a fifty day moving average price of $8.91 and a 200 day moving average price of $8.29. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $10.94. The company has a market cap of $2.54 billion, a PE ratio of -5.62 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s quarterly revenue was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 earnings per share. Analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.66 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.